Marc F. Botteman

Marc F. Botteman

Auto-generated profile, based on publicly available information

Marc F. Botteman

Pharmerit – an OPEN Health Company, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2006 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
MBM. Botteman
M. Botteman
VBV. Barghout
V. Barghout
JSJ. Stephens
J. Stephens
JHJ. Hay
J. Hay
JBJ. Brandman
J. Brandman
MAM. Aapro
M. Aapro
Background: Bisphosphonates are recommended to prevent skeletal related events (SREs) in patients with breast cancer and bone metastases (BCBM). However, their clinical and economic profiles vary from one agent to the other. Materials and methods: Using modeling techniques, we simulated from the perspective of the UK's National Health Service (NHS) the cost and quality adjusted survival (QALY) associated with five commonly-used bisphosphonates or no therapy in this patient population. The simulation followed patients into several health states (i.e. alive or dead, experiencing an SRE or no SRE, and receiving first or second line therapy). Drugs costs, infusion costs, SREs costs, and utility values were estimated from published sources. Utilities were applied to time with and without SREs to capture the impact on quality of life. Results: Compared to no therapy, all bisphosphonates are either cost saving or highly cost-effective (with a cost per QALY ≤ £6126). Within this evaluation, zoledronic acid was more effective and less expensive than all other options. Conclusions: Based on our model, the use of bisphosphonates in breast cancer patients with bone metastases should lead to improved patient outcomes and cost savings to the NHS and possibly other similar entities.

25 March 2019 in Journal of Medical Economics
Verified
Journal Article
Open access
AAAbdalla Aly
Abdalla Aly
CJCourtney Johnson
Courtney Johnson
SYShuo Yang
Shuo Yang
MBMarc F. Botteman
Marc F. Botteman
SRSumati Rao
Sumati Rao
AHArif Hussain
Arif Hussain
Aims: Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT) but invariably progress, requiring additional LOTs and healthcare resource use (HCRU). To better understand the evolving mUC treatment landscape, we estimated the economic burden of chemotherapy-based mUC treatments among US Medicare patients. Methods: Newly diagnosed Medicare patients with mUC were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Patients were followed from diagnosis to death, disenrollment, or end of study to characterize LOTs (first [LOT1], second [LOT2], and third+ [LOT3+]). Kaplan-Meier methods were used to estimate overall survival (OS) by LOT. HCRU and mean costs were reported over the follow-up period, LOT duration, or maximum LOT received. Results: Among 1873 eligible patients with mUC (median age, 77 years; median follow-up, 7.5 months), 1035 (55%) received no chemotherapy. Among chemotherapy-treated patients, 61% had LOT1 only, 25% had LOT1 and LOT2 only, and 14% had ≥3 LOTs. Median OS was 8.1 months, range 4.3 (untreated) to 29.8 (LOT3+) months. HCRU frequency increased with additional LOTs. Mean cumulative per-patient cost was $82,912 for all patients, increasing with additional LOTs (untreated, $57,207; LOT1, $99,213; LOT2, $125,190; LOT3+, $163,884). Mean per-patient, per-month cost was $18,827 for all patients, decreasing with increasing number of LOTs received (untreated, $27,211; LOT1, $9601; LOT2, $7325; LOT3+, $6017). Limitations: Potential for treatment misclassification when using the algorithm defining LOTs and non-generalizability of results to younger patients. Conclusions: Over 50% of Medicare patients with mUC received no chemotherapy. Among chemotherapy-treated patients, most received only one LOT. Additional LOTs led to higher mean costs and HCRU, but as patients were followed longer, monthly costs decreased. As treatments evolve to include immuno-oncology agents, these findings provide a clinically-relevant economic benchmark for mUC treatment across different traditional LOTs.

21 April 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
CSCaitlyn T. Solem
Caitlyn T. Solem
MVMontserrat Vera-Llonch
Montserrat Vera-Llonch
SLSizhu Liu
Sizhu Liu
MBMarc Botteman
Marc Botteman
BCBrenda Castiglione
Brenda Castiglione
The analysis aimed to examine the impact of pulmonary exacerbations (PEs) and lung function on generic measures of HRQL in patients with cystic fibrosis (CF) using trial-based data. In a 48-week randomized, placebo-controlled study of ivacaftor in patients ≥12 years with CF and a G551D-CFTR mutation the relationship between PEs, PE-related hospitalizations and percent predicted forced expiratory volume in one second (ppFEV1) with EQ-5D measures (index and visual analog scale [VAS]) was examined in post-hoc analyses. Multivariate mixed-effects models were employed to describe the association of PEs, PE-related hospitalizations, and ppFEV1 on EQ-5D measures. One hundred sixty one patients (age: mean 25.5 [SD 9.5] years; baseline ppFEV1: 63.6 [16.4]) contributed 1,214 observations (ppFEV1: no lung dysfunction [n = 157], mild [n = 419], moderate [n = 572], severe [n = 66]). Problems were most frequently reported on pain/discomfort, anxiety/depression, and usual activities EQ-5D items. The mean (SE) EQ-5D index nominally decreased (worsened) with worsening severity of lung dysfunction (P = 0.070): 0.931 (0.023); mild: 0.923 (0.021); moderate: 0.904 (0.018); severe: 0.870 (0.020). 146 PEs were experienced by 72 patients, including 52 PEs (35.6 %) that required hospitalization. Mean EQ-5D index and VAS scores were lowest (worst) within 1 week (before or after PE start) for PEs requiring hospitalization. Pulmonary exacerbations, PE-related hospitalizations, and ppFEV1 were significant predictors of EQ-5D index and VAS. In a clinical study of patients with CF (≥12 years of age and a G551D-CFTR mutation), PEs, primarily those requiring hospitalization, were associated with low EQ-5D index and VAS scores. The impact of ppFEV1 was relatively smaller. Reducing PEs, in particular those requiring hospitalization, would likely improve HRQL among these patients. ClinicalTrials.gov, NCT00909532 ; URL: clinicaltrials.gov, May 26, 2009

5 September 2012 in Journal of Medical Economics
Verified
Journal Article
Closed access
SSSonya J. Snedecor
Sonya J. Snedecor
JCJohn Carter
John Carter
SKSatyin Kaura
Satyin Kaura
MBMarc F. Botteman
Marc F. Botteman
Denosumab has been approved in the US for skeletal-related event (SRE) prevention in bone-metastatic prostate cancer on the basis of a phase III clinical trial in which denosumab reduced SREs relative to zoledronic acid. Overall survival, disease progression, and serious adverse events did not differ significantly between groups. This analysis assessed the cost-effectiveness of denosumab vs zoledronic acid in bone-metastatic prostate cancer from a US payer perspective. A literature-based Markov model, wherein inputs were selected to reproduce clinical trial outcomes, was developed to estimate the survival, quality-adjusted life-years (QALYs), number and costs of SREs, and drug and administration costs for patients receiving denosumab or zoledronic acid over 27 months. QALYs were estimated by assigning health-state utilities. SRE-related costs and utilities were literature-based. Outcomes were discounted 3% per annum, and model robustness was tested via scenario, univariate, and probabilistic sensitivity analyses. Denosumab resulted in fewer estimated SREs (−0.241; 1.036 vs 1.277), more QALYs (0.0074; 0.9306 vs 0.9232), and lower SRE-related costs (−$2340; $8824 vs $11,164), but higher drug-related costs ($10,181; $23,144 vs $12,963) and total costs ($7841; $31,968 vs $24,127) vs zoledronic acid. The base case estimated cost per QALY-gained was $1,058,741. This analysis was limited by the restricted availability of clinical data and the need to use projection methods beyond the trial time frame. However, a wide range of scenarios predicted denosumab to have an incremental cost/QALY gained above what may be considered acceptable value for money in the US. This raises important questions regarding the pharmacoeconomic value of denosumab in bone-metastatic prostate cancer.

1 March 2020 in Ophthalmology Glaucoma
Verified
Journal Article
Open access
IAIqbal Ike K. Ahmed
Iqbal Ike K. Ahmed
DPDominik W. Podbielski
Dominik W. Podbielski
VPVardhaman Patel
Vardhaman Patel
HFHeather Falvey
Heather Falvey
JMJudith Murray
Judith Murray
RGRon Goeree
Ron Goeree
To assess, from the Canadian public payer perspective, the cost-utility of implanting iStent Inject trabecular bypass stent (TBS) devices in conjunction with cataract surgery versus cataract surgery alone in patients with open-angle glaucoma (OAG) and visually significant cataract. Cost-utility analysis using efficacy and safety results of pivotal randomized clinical trial. Modeled cohort of patients with OAG (83.1% with mild disease, 16.9% with moderate disease) and visually significant cataract. Open-angle glaucoma treatment costs and effects were projected over a 15-year time horizon using a Markov model with Hodapp-Parrish-Anderson glaucoma stages (mild, moderate, advanced, severe or blind) and death as health states. Patients in the mild or moderate OAG health states received implantation of iStent Inject during cataract surgery versus cataract surgery alone. On worsening of visual field defect and optic disc damage, patients could receive selective laser trabeculoplasty and trabeculectomy. We measured treatment effect as reduction in intraocular pressure (IOP) and mean medication use and estimated transition probabilities based on efficacy-adjusted visual field mean deviation decline per month. Healthcare resource utilization and utility scores were obtained from the literature. Cost inputs (2017 Canadian dollars [C$]) were derived using the Ontario Health Insurance Plan, expert opinion, medication claims datasets, and Ontario Drug Benefit Formulary medication consumption costs. We conducted deterministic and probabilistic sensitivity analyses to examine the impact of alternative model input values on results. Incremental cost per quality-adjusted life year (QALY) gained. Compared with cataract surgery alone, TBS plus cataract surgery showed a 99% probability of being more effective (+0.023 QALYs; 95% confidence interval [CI], 0.004 to 0.044) and a 73.7% probability of being cost-saving (net cost, -C$389.00; 95% CI, -C$1712.00 to C$850.70). In 95% of all simulations, TBS plus cataract surgery showed a cost per QALY of C$62 366 or less. Results were robust in additional sensitivity and scenario analyses. iStent Inject TBS implantation during cataract surgery seems to be cost effective for reducing IOP in patients with mild to moderate OAG versus cataract surgery alone.

1 January 2007 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
MBMarc F. Botteman
Marc F. Botteman
RORon J. Ozminkowski
Ron J. Ozminkowski
SWShaohung Wang
Shaohung Wang
CPChris L. Pashos
Chris L. Pashos
KSKendyl Schaefer
Kendyl Schaefer
DFDaniel J. Foley
Daniel J. Foley